Gastric CancerDRTSTNCT03277144
Incidence of Duodenal Stump Fistula After Gastrectomy for Gastric Cancer. A Randomized Controlled Trial
A study testing TST-TriStaple(3lines stapler)Technology and other conventional techniques in people with Gastric Cancer and Duodenal Stump Leak, run by University of Turin, Italy at 1 site in Italy.
Trial summary
The goal of this trial is to demonstrate that the use of Tri-Staple Technology for duodenal resection during open gastrectomy for cancer is safer than the use of other conventional methods of resection/closure of the duodenum and that the incidence of duodenal fistula can be decreased to that observed after the use of… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Gastric Cancer, Duodenal Stump Leak
- What is being tested?
- TST-TriStaple(3lines stapler)Technology and other conventional techniques
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 700 participants
- Where
- 1 siteItaly
- Study dates
- 11 Sep 2017to 1 Oct 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- pathologically proven malign tumor of the stomach
- age of 18 to 80 years,
- no history of other cancers
- no history of radiotherapy in supra-mesocolic space
- total or distal gastrectomy without anastomosis with the duodenum
Who cannot join
- emergency surgery
- American Society of Anesthesiologists class > 3
- need for combined resection of other organs
- laparoscopic/robotic access
- severe heart disease
- liver cirrhosis
Show all 10Show fewer
- T stage >cT4a
- citology positive at preoperative laparoscopy
- cM+ (clinical suspicion of distant metastasis)
- cD+ (clinical suspicion of duodenal involvment)
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
San Luigi University Hospital
Orbassano, Turin
Maurizio Degiuli, Professor, +390119026525, maurizio.degiuli@unito.it
About this study
Official title: Does the Technique of Duodenal Resection Affect the Incidence of Duodenal Stump Fistula After Gastrectomy for Gastric Cancer ? A Randomized Controlled Trial (DRTST: Duodenal Resection Tri-staple Technology)
The goal of this trial is to demonstrate that the use of Tri-Staple Technology for duodenal resection during open gastrectomy for cancer is safer than the use of other conventional methods of resection/closure of the duodenum and that the incidence of duodenal fistula can be decreased to that observed after the use of this technology in Laparoscopic and robotic gastrectomy, therefore almost three times lower than that currently reported in literature.
Participating centres must have an annual volume of at least 20 gastrectomies per year.
Read the detailed description
BACKGROUND Gastric cancer is still one of the most frequent malignancies in Europe. In United States the estimated new cases in 2010 were 21000 (12730 male and 8270 female) with 10570 estimated deaths (6350 male and 4220 female)[7,8]. In Italy the estimated new cases in 2013 were 13200 (7900 males and 5300 female) (AIOM-AIRTUM, I numeri del cancro in Italia - 2013, www.registri-tumori.it) .The incidence rates in 2005-2009 were 21.6 and 10.8 per 100,000 in males and females respectively. The mortality rates in 2005-2009 were 14.9 and 7.3 per 100,000 in males and females respectively. (www.itacan.ispo.toscana.it).A total or subtotal gastrectomy with D2 lymph node dissection and R0 margins remains the standard of care for gastric cancer[9,10]. Despite this, in low-volume centers gastrectomy still remains a challenging procedure with a notable morbidity rate (33%-43%) and mortality rate (7%-12%)[11,12]. Duodenal stump fistula (DSF) represents an infrequent but severe complication after total or subtotal gastrectomy for gastric cancer, with incidence of 2,5 - 5% and mortality rate ranging from 7% to 67%(1-5). Several factors were identified as possible cause of DSF, such as local hematoma, inflammation, intra-operative inadequate closure of the duodenal stump, incorrect drain position, devascularization, post-operative distension of the duodenum and R1-R2 resections[2,13].
There are many DSF-related complications leading to longer hospitalization times, such as intra-abdominal abscesses, wound infections, diffuse peritonitis, sepsis, malnutrition, pancreatitis, abdominal bleeding, and pneumonia. (3) DSF is often difficult to treat because of the highly enzyme-rich duodenal juice and deep location of the fistula. In a retrospective multicenter study (2) 3,685 patients undergoing gastrectomy for malignancies who developed 68 DSFs were analyzed; it was reported that DSF features had changed in the last 30 years and that DSF alone no longer leads to death; some complications observed in the past, such as fluid and electrolyte loss and dermatitis, have disappeared owing to improvements( in particular parenteral nutrition and wound care). However, additional new complications such as bleeding and fistulas of neighboring organs were emerging. Although medical therapy is associated with better outcomes, surgery is still mandatory in cases of severe abdominal sepsis or bleeding not otherwise manageable.
However, reoperation is often ineffective owing to postoperative edema and inflammation, and the prognosis of patients undergoing surgery for DSF remains very poor. To improve the outcome of these patients, many surgical procedures have been proposed from washing the peritoneal cavity and abdominal drainage to tube duodenostomy (14,15), closure of the fistula, fistula repair with a rectus abdominis flap (16), fistula closure by Roux-en-Y duodenojejunostomy(17,18), biliogastric diversion, laparostomy, and pancreatoduodenectomy (19) but surgeons are often unsure about the best management and the result are often unsuccessful.
In a recent Korean national RCT (6) on open (ODG) vs laparoscopic distal gastrectomy (LADG), the incidence of duodenal stump leakage after laparoscopyc gastrectomy was about 1%; in this population study the use of tri-staple technology for duodenal resection was mandatory. In our clinical practice, the incidence of DSF after open gastrectomy is about 3-5% adopting different techniques of duodenal stump resection/closure.
The aim of this study is to evaluate if duodenal stump resection/closure using tri-staple technology can significantly decrease the incidence of DSF after open gastrectomy as compared to the other conventional methods adopted in the clinical practice (1% vs 5%).
We have designed a national multicentre pragmatic (20) RCT to compare the use of endoGIA or Echelon (triStaple technology) to other conventional methods (GIA with or without manual reinforcement , manual suture, purse string) for duodenal resection/closure during open gastrectomy, with the assumption that Tri-staple technology without reinforcement ( as routinely used in LADG) is the safest method.
AIM OF THE STUDY The goal of this trial is to demonstrate that the use of Tri-Staple Technology for duodenal resection during open gastrectomy for cancer is safer than the use of other conventional methods of resection/closure of the duodenum and that the incidence of duodenal fistula can be decreased to that observed after the use of this technology in Laparoscopic and robotic gastrectomy, therefore almost three times lower than that currently reported in literature.
Participating centres must have an annual volume of at least 20 gastrectomies per year.
Design of the study This is a multicentre randomized controlled trial.
Patients with malignant tumor of the stomach, as primary diagnosis, requiring distal or total gastrectomy without anastomosis with the duodenum will undergo clinical preoperative workout and anaesthesiologist evaluation. All patients who meet the inclusion/exclusion criteria and agree to sign the informed consent are registered into the trial and randomized to one of the two arms (a. Duodenal Stump Closure with TriStaple Technology - TST or b. Duodenal Stump closure with other conventional techniques - OCT ) as described in the chapter Randomization. In TST arm no manual reinforce of the mechanical suture should be perfomed; in OCT group, a manual reinforce of the suture can be done according to the preference of the operator, and recorded in the trial data base (DB).
Patients' postoperative course will be carefully monitored and all variables detailed below will be recorded in the DB.
DSF will be diagnosed by the presence of duodenal fluid in the surgical drainage and confirmed by a CT scan when needed (presence of intra-abdominal peri-duodenal collection of fluid and/or micro air bubbles).
Also the type of treatment (conservative, percutaneous drainage, reoperation, others ) of DSF should be recorded, as well as the length of hospital stay and other postoperative complications or in-hospital death ( as well as 30- and 90- days mortality)
Trial setting
This is an Italian national multicentre RCT; the Division of General Surgery from University of Turin, Department of Surgical Sciences, AOU San Luigi Gonzaga di Orbassano, will be the Coordinating Centre of the trial. The P.I. of the trial is Prof Maurizio Degiuli.
S.S.D. Epidemiologia, Clinica e Valutativa, AOU Città della Salute e della Scienza di Torino, will be responsible for this trial's central randomisation and statistical analysis.
Clinical monitoring and data managing will be performed by the P.I. and and co-investigators.
Study population
inclusion criteria
pathologically proven malign tumor of the stomach age of 18 to 80 years, no history of other cancers no history of radiotherapy in supra-mesocolic space total or distal gastrectomy without anastomosis with the duodenum
exclusion criteria
emergency surgery American Society of Anesthesiologists class > 3 need for combined resection of other organs laparoscopic/robotic access severe heart disease liver cirrhosis T stage >cT4a citology positive at preoperative laparoscopy cM+ cD+
All patients freely give informed consent to participate in the study prior to surgery, at the time of discussing the intervention with the surgeon or the nurse and can decide to withdraw from the study at any time.
Diagnosis of DSF
A diagnosis of DF is made on the basis of the presence of duodenal juice in the surgical drainage or its leakage through the abdominal wall, and confirmed by CT scan and/or fistulography.
Variables
sex age ASA score COPD type 2 DM multiple comorbidities pre-operative albumin serum levels pre-operative lymphocytes blood count cT Stage / pTStage pTNM distal margin involvement intraoperative blood loss lenght of hospital stay Type of gastrectomy TG vs DG type of reconstruction: ( BII vs RY) lymph node dissection: D1, D1+, D2, > D2
Type of duodenal stump closure device:
- endoGIA tristaple B. other techniques (GIA/TA with or without manual reinforcement (simple interrupted suture or running suture), manual suture (simple interrupted or running suture), purse string)
Development of DSF (po day) healing of DSF (po day) Diagnosis of DSF Daily output of DSF Type of treatment of DSF Other postoperative morbidity according to Dindo. Postoperative mortality
Randomisation
All patients who meet the inclusion/exclusion criteria and give the informed consent to participate are registered into the central trial database and centrally randomized to one of the two groups (a. Duodenal Stump Closure with TriStaple Technology - TST or b. Duodenal Stump closure with other conventional techniques - OCT ).
Patients refusing recruitment are treated with usual care and contribute to the database a limited set of pre-defined information.
Result of randomisation is communicated to the surgical team at the time of their entrance in the surgical theatre.
Sample size calculation and statistical analysis
Assuming an alpha error at the 5% level and power 80%, a total of 700 patients (350 per arm) are required in order to recognise a true difference of 5% in (a) vs 1% in (b).
Assuming an average case volume of 20 patients per year and 60% acceptance rate, about 30 Centres recruiting for two years will need to be involved.
Cox regression with multivariable analysis will be performed
Data property
Results will be the property of Università degli studi di Torino and of the researchers involved in the conduction of the mulicentre project. A scientific committee will be constituted comprising a lead investigator from each of the Centres.
- Conditions
- Gastric Cancer, Duodenal Stump Leak
- Being tested
- TST-TriStaple(3lines stapler)Technology, other conventional techniques
- Keywords
- linear stapler
- Medical subject headings
- Stomach Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TST-TriStaple(3lines stapler)TechnologyDevice
Duodenal stump closed using a Tristaple ( three-lines linear stapler) device
other conventional techniquesOther
Also called double-line linear stapler with manual reinforcement, manual suture, purse string suture, double-line linear stapler without manual reinforcement
Duodenal stump closed using other conventional techniques entailing manual suture or mechanical devices with only two lines of sutures.
| Study group | Role | What they receive |
|---|---|---|
| TST-TriStaple(3lines stapler)Technology | Experimental | During gastrectomy for gatric cancer without anastomosis with the duodenum, Duodenal Stump is closed with a TriStaple (three-lines linear stapler) Technology device. Receives: Device: TST-TriStaple(3lines stapler)Technology |
| OCT (other conventional techniques) | Active comparator | During gastrectomy for gatric cancer without anastomosis with the duodenum, Duodenal Stump is closed with conventional techniques including manual sutures and devices with only two lines of staples. Receives: Other: other conventional techniques |
What is being measured
The primary outcome is the main question the study is designed to answer.
incidence of duodenal stump leak
The aim of this study is to evaluate if duodenal stump closure using tri-staple technology can significantly decrease the incidence of duodenal stump leakage to 1% as compared to other conventional methods (5%). So the primary endpoint is :
- incidence of DSF, diagnosed on the basis of the presence of duodenal juice in the surgical drainage or its leakage through the abdominal wall, and confirmed by CT scan and/or fistulography.
Measured: within 30/60 days from operation
Secondary outcomes (7)
cost of surgery
cost of devices, hospital stay, drugs, examinations
Measured: within 90 days from operation
operative time for duodenal stump closure
time ( min) necessary for duodenal stump closure
Measured: intraopeartively
short-term postoperative complications
onset of postoperative complications according to Clavien-Dindo classification
Measured: within 30 days from operation
blood loss
intraoperative blood loss (ml)
Measured: intraopeartively
lenght of hospitalization
duration (days) of hospital stay after operation
Measured: 120 days after operation
Operative mortality
post-operative death
Measured: 30 and 60 days after operation
Frequency of DSF by surgical volume
rate of duodenal stump leak of every participating center
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2017
- Study start11 Sep 2017
- Primary completion11 Sep 2018 (estimated)
- Study completion1 Oct 2019 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (20)Papers the sponsor has linked to this study.
- Other trials for Gastric CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- All gastric cancer patients who meet the inclusion/exclusion criteria and give the informed consent to participate are registered into the central trial database and centrally permuted-block randomized to one of the two arms (a. Duodenal Stump Closure with TriStaple Technology - TST or b. Duodenal Stump closure with other conventional techniques - OCT ).
- Masking
- None (open label)
- Enrolment
- 700 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Turin, Italy
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Maurizio Degiuli, University of Turin, Italy
- Investigators
- Maurizio Degiuli, MD Prof, Principal investigator, University of Turin, San Luigi University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03277144
- Sponsor's protocol ID
- DRTST.01
- Acronym
- DRTST
- Status last verified
- Sep 2017
- First submitted
- 6 Sep 2017
- Last updated
- 18 Sep 2017
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Publications
Inghelmann R, Grande E, Francisci S, Verdecchia A, Micheli A, Baili P, Capocaccia R, De Angelis R. Regional estimates of stomach cancer burden in Italy. Tumori. 2007 Jul-Aug;93(4):367-73. doi: 10.1177/030089160709300407.
PubMed 17899867Aurello P, Bellagamba R, Rossi Del Monte S, D'Angelo F, Nigri G, Cicchini C, Ravaioli M, Ramacciato G. Apoptosis and microvessel density in gastric cancer: correlation with tumor stage and prognosis. Am Surg. 2009 Dec;75(12):1183-8.
PubMed 19999909Aurello P, Magistri P, Nigri G, Petrucciani N, Novi L, Antolino L, D'Angelo F, Ramacciato G. Surgical management of microscopic positive resection margin after gastrectomy for gastric cancer: a systematic review of gastric R1 management. Anticancer Res. 2014 Nov;34(11):6283-8.
PubMed 25368226Martin RC 2nd, Jaques DP, Brennan MF, Karpeh M. Achieving RO resection for locally advanced gastric cancer: is it worth the risk of multiorgan resection? J Am Coll Surg. 2002 May;194(5):568-77. doi: 10.1016/s1072-7515(02)01116-x.
PubMed 12025834Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008 Nov 11;337:a2390. doi: 10.1136/bmj.a2390.
PubMed 19001484Orsenigo E, Bissolati M, Socci C, Chiari D, Muffatti F, Nifosi J, Staudacher C. Duodenal stump fistula after gastric surgery for malignancies: a retrospective analysis of risk factors in a single centre experience. Gastric Cancer. 2014 Oct;17(4):733-44. doi: 10.1007/s10120-013-0327-x. Epub 2014 Jan 8.
PubMed 24399492Cozzaglio L, Coladonato M, Biffi R, Coniglio A, Corso V, Dionigi P, Gianotti L, Mazzaferro V, Morgagni P, Rosa F, Rosati R, Roviello F, Doci R. Duodenal fistula after elective gastrectomy for malignant disease : an italian retrospective multicenter study. J Gastrointest Surg. 2010 May;14(5):805-11. doi: 10.1007/s11605-010-1166-2. Epub 2010 Feb 9.
PubMed 20143272Rossi JA, Sollenberger LL, Rege RV, Glenn J, Joehl RJ. External duodenal fistula. Causes, complications, and treatment. Arch Surg. 1986 Aug;121(8):908-12. doi: 10.1001/archsurg.1986.01400080050009.
PubMed 3729708EDMUNDS LH Jr, WILLIAMS GM, WELCH CE. External fistulas arising from the gastro-intestinal tract. Ann Surg. 1960 Sep;152(3):445-71. doi: 10.1097/00000658-196009000-00009. No abstract available.
PubMed 13725742Tarazi R, Coutsoftides T, Steiger E, Fazio VW. Gastric and duodenal cutaneous fistulas. World J Surg. 1983 Jul;7(4):463-73. doi: 10.1007/BF01655935. No abstract available.
PubMed 6624121Kim W, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, Cho GS, Kim CY, Yang HK, Park DJ, Song KY, Lee SI, Ryu SY, Lee JH, Lee HJ; Korean Laparo-endoscopic Gastrointestinal Surgery Study (KLASS) Group. Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01). Ann Surg. 2016 Jan;263(1):28-35. doi: 10.1097/SLA.0000000000001346.
PubMed 26352529Pedrazzani C, Marrelli D, Rampone B, De Stefano A, Corso G, Fotia G, Pinto E, Roviello F. Postoperative complications and functional results after subtotal gastrectomy with Billroth II reconstruction for primary gastric cancer. Dig Dis Sci. 2007 Aug;52(8):1757-63. doi: 10.1007/s10620-006-9655-6. Epub 2007 Apr 3.
PubMed 17404848McCulloch P, Ward J, Tekkis PP; ASCOT group of surgeons; British Oesophago-Gastric Cancer Group. Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort study. BMJ. 2003 Nov 22;327(7425):1192-7. doi: 10.1136/bmj.327.7425.1192.
PubMed 14630753Cozzaglio L, Cimino M, Mauri G, Ardito A, Pedicini V, Poretti D, Brambilla G, Sacchi M, Melis A, Doci R. Percutaneous transhepatic biliary drainage and occlusion balloon in the management of duodenal stump fistula. J Gastrointest Surg. 2011 Nov;15(11):1977-81. doi: 10.1007/s11605-011-1668-6. Epub 2011 Sep 13.
PubMed 21913043Levy E, Cugnenc PH, Frileux P, Hannoun L, Parc R, Huguet C, Loygue J. Postoperative peritonitis due to gastric and duodenal fistulas. Operative management by continuous intraluminal infusion and aspiration: report of 23 cases. Br J Surg. 1984 Jul;71(7):543-6. doi: 10.1002/bjs.1800710725.
PubMed 6733430
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Does the Technique of Duodenal Resection Affect the Incidence of Duodenal Stump Fistula After Gastrectomy for Gastric Cancer ? A Randomized Controlled Trial (DRTST: Duodenal Resection Tri-staple Technology)
- ClinicalTrials.gov ID
- NCT03277144
- Acronym / sponsor ID
- DRTST / DRTST.01
- Conditions
- Gastric Cancer, Duodenal Stump Leak
- Keywords
- linear stapler
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 700 participants (estimated)
- Lead sponsor
- University of Turin, ItalyUniversity, hospital or other
- Study start
- 11 Sep 2017 (actual)
- Primary completion
- 11 Sep 2018 (estimated)
- Study completion
- 1 Oct 2019 (estimated)
- First posted
- 8 Sep 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this trial is to demonstrate that the use of Tri-Staple Technology for duodenal resection during open gastrectomy for cancer is safer than the use of other conventional methods of resection/closure of the duodenum and that the incidence of duodenal fistula can be decreased to that observed after the use of this technology in Laparoscopic and robotic gastrectomy, therefore almost three times lower than that currently reported in literature.
Participating centres must have an annual volume of at least 20 gastrectomies per year.
Detailed description
BACKGROUND Gastric cancer is still one of the most frequent malignancies in Europe. In United States the estimated new cases in 2010 were 21000 (12730 male and 8270 female) with 10570 estimated deaths (6350 male and 4220 female)[7,8]. In Italy the estimated new cases in 2013 were 13200 (7900 males and 5300 female) (AIOM-AIRTUM, I numeri del cancro in Italia - 2013, www.registri-tumori.it) .The incidence rates in 2005-2009 were 21.6 and 10.8 per 100,000 in males and females respectively. The mortality rates in 2005-2009 were 14.9 and 7.3 per 100,000 in males and females respectively. (www.itacan.ispo.toscana.it).A total or subtotal gastrectomy with D2 lymph node dissection and R0 margins remains the standard of care for gastric cancer[9,10]. Despite this, in low-volume centers gastrectomy still remains a challenging procedure with a notable morbidity rate (33%-43%) and mortality rate (7%-12%)[11,12]. Duodenal stump fistula (DSF) represents an infrequent but severe complication after total or subtotal gastrectomy for gastric cancer, with incidence of 2,5 - 5% and mortality rate ranging from 7% to 67%(1-5). Several factors were identified as possible cause of DSF, such as local hematoma, inflammation, intra-operative inadequate closure of the duodenal stump, incorrect drain position, devascularization, post-operative distension of the duodenum and R1-R2 resections[2,13].
There are many DSF-related complications leading to longer hospitalization times, such as intra-abdominal abscesses, wound infections, diffuse peritonitis, sepsis, malnutrition, pancreatitis, abdominal bleeding, and pneumonia. (3) DSF is often difficult to treat because of the highly enzyme-rich duodenal juice and deep location of the fistula. In a retrospective multicenter study (2) 3,685 patients undergoing gastrectomy for malignancies who developed 68 DSFs were analyzed; it was reported that DSF features had changed in the last 30 years and that DSF alone no longer leads to death; some complications observed in the past, such as fluid and electrolyte loss and dermatitis, have disappeared owing to improvements( in particular parenteral nutrition and wound care). However, additional new complications such as bleeding and fistulas of neighboring organs were emerging. Although medical therapy is associated with better outcomes, surgery is still mandatory in cases of severe abdominal sepsis or bleeding not otherwise manageable.
However, reoperation is often ineffective owing to postoperative edema and inflammation, and the prognosis of patients undergoing surgery for DSF remains very poor. To improve the outcome of these patients, many surgical procedures have been proposed from washing the peritoneal cavity and abdominal drainage to tube duodenostomy (14,15), closure of the fistula, fistula repair with a rectus abdominis flap (16), fistula closure by Roux-en-Y duodenojejunostomy(17,18), biliogastric diversion, laparostomy, and pancreatoduodenectomy (19) but surgeons are often unsure about the best management and the result are often unsuccessful.
In a recent Korean national RCT (6) on open (ODG) vs laparoscopic distal gastrectomy (LADG), the incidence of duodenal stump leakage after laparoscopyc gastrectomy was about 1%; in this population study the use of tri-staple technology for duodenal resection was mandatory. In our clinical practice, the incidence of DSF after open gastrectomy is about 3-5% adopting different techniques of duodenal stump resection/closure.
The aim of this study is to evaluate if duodenal stump resection/closure using tri-staple technology can significantly decrease the incidence of DSF after open gastrectomy as compared to the other conventional methods adopted in the clinical practice (1% vs 5%).
We have designed a national multicentre pragmatic (20) RCT to compare the use of endoGIA or Echelon (triStaple technology) to other conventional methods (GIA with or without manual reinforcement , manual suture, purse string) for duodenal resection/closure during open gastrectomy, with the assumption that Tri-staple technology without reinforcement ( as routinely used in LADG) is the safest method.
AIM OF THE STUDY The goal of this trial is to demonstrate that the use of Tri-Staple Technology for duodenal resection during open gastrectomy for cancer is safer than the use of other conventional methods of resection/closure of the duodenum and that the incidence of duodenal fistula can be decreased to that observed after the use of this technology in Laparoscopic and robotic gastrectomy, therefore almost three times lower than that currently reported in literature.
Participating centres must have an annual volume of at least 20 gastrectomies per year.
Design of the study This is a multicentre randomized controlled trial.
Patients with malignant tumor of the stomach, as primary diagnosis, requiring distal or total gastrectomy without anastomosis with the duodenum will undergo clinical preoperative workout and anaesthesiologist evaluation. All patients who meet the inclusion/exclusion criteria and agree to sign the informed consent are registered into the trial and randomized to one of the two arms (a. Duodenal Stump Closure with TriStaple Technology - TST or b. Duodenal Stump closure with other conventional techniques - OCT ) as described in the chapter Randomization. In TST arm no manual reinforce of the mechanical suture should be perfomed; in OCT group, a manual reinforce of the suture can be done according to the preference of the operator, and recorded in the trial data base (DB).
Patients' postoperative course will be carefully monitored and all variables detailed below will be recorded in the DB.
DSF will be diagnosed by the presence of duodenal fluid in the surgical drainage and confirmed by a CT scan when needed (presence of intra-abdominal peri-duodenal collection of fluid and/or micro air bubbles).
Also the type of treatment (conservative, percutaneous drainage, reoperation, others ) of DSF should be recorded, as well as the length of hospital stay and other postoperative complications or in-hospital death ( as well as 30- and 90- days mortality)
Trial setting
This is an Italian national multicentre RCT; the Division of General Surgery from University of Turin, Department of Surgical Sciences, AOU San Luigi Gonzaga di Orbassano, will be the Coordinating Centre of the trial. The P.I. of the trial is Prof Maurizio Degiuli.
S.S.D. Epidemiologia, Clinica e Valutativa, AOU Città della Salute e della Scienza di Torino, will be responsible for this trial's central randomisation and statistical analysis.
Clinical monitoring and data managing will be performed by the P.I. and and co-investigators.
Study population
inclusion criteria
pathologically proven malign tumor of the stomach age of 18 to 80 years, no history of other cancers no history of radiotherapy in supra-mesocolic space total or distal gastrectomy without anastomosis with the duodenum
exclusion criteria
emergency surgery American Society of Anesthesiologists class > 3 need for combined resection of other organs laparoscopic/robotic access severe heart disease liver cirrhosis T stage >cT4a citology positive at preoperative laparoscopy cM+ cD+
All patients freely give informed consent to participate in the study prior to surgery, at the time of discussing the intervention with the surgeon or the nurse and can decide to withdraw from the study at any time.
Diagnosis of DSF
A diagnosis of DF is made on the basis of the presence of duodenal juice in the surgical drainage or its leakage through the abdominal wall, and confirmed by CT scan and/or fistulography.
Variables
sex age ASA score COPD type 2 DM multiple comorbidities pre-operative albumin serum levels pre-operative lymphocytes blood count cT Stage / pTStage pTNM distal margin involvement intraoperative blood loss lenght of hospital stay Type of gastrectomy TG vs DG type of reconstruction: ( BII vs RY) lymph node dissection: D1, D1+, D2, > D2
Type of duodenal stump closure device:
- endoGIA tristaple B. other techniques (GIA/TA with or without manual reinforcement (simple interrupted suture or running suture), manual suture (simple interrupted or running suture), purse string)
Development of DSF (po day) healing of DSF (po day) Diagnosis of DSF Daily output of DSF Type of treatment of DSF Other postoperative morbidity according to Dindo. Postoperative mortality
Randomisation
All patients who meet the inclusion/exclusion criteria and give the informed consent to participate are registered into the central trial database and centrally randomized to one of the two groups (a. Duodenal Stump Closure with TriStaple Technology - TST or b. Duodenal Stump closure with other conventional techniques - OCT ).
Patients refusing recruitment are treated with usual care and contribute to the database a limited set of pre-defined information.
Result of randomisation is communicated to the surgical team at the time of their entrance in the surgical theatre.
Sample size calculation and statistical analysis
Assuming an alpha error at the 5% level and power 80%, a total of 700 patients (350 per arm) are required in order to recognise a true difference of 5% in (a) vs 1% in (b).
Assuming an average case volume of 20 patients per year and 60% acceptance rate, about 30 Centres recruiting for two years will need to be involved.
Cox regression with multivariable analysis will be performed
Data property
Results will be the property of Università degli studi di Torino and of the researchers involved in the conduction of the mulicentre project. A scientific committee will be constituted comprising a lead investigator from each of the Centres.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- All gastric cancer patients who meet the inclusion/exclusion criteria and give the informed consent to participate are registered into the central trial database and centrally permuted-block randomized to one of the two arms (a. Duodenal Stump Closure with TriStaple Technology - TST or b. Duodenal Stump closure with other conventional techniques - OCT ).
| Arm | Type | Receives |
|---|---|---|
| TST-TriStaple(3lines stapler)Technology | Experimental | Device: TST-TriStaple(3lines stapler)TechnologyDuring gastrectomy for gatric cancer without anastomosis with the duodenum, Duodenal Stump is closed with a TriStaple (three-lines linear stapler) Technology device. |
| OCT (other conventional techniques) | Active comparator | Other: other conventional techniquesDuring gastrectomy for gatric cancer without anastomosis with the duodenum, Duodenal Stump is closed with conventional techniques including manual sutures and devices with only two lines of staples. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- pathologically proven malign tumor of the stomach
- age of 18 to 80 years,
- no history of other cancers
- no history of radiotherapy in supra-mesocolic space
- total or distal gastrectomy without anastomosis with the duodenum
Key exclusion criteria (10 listed)
- emergency surgery
- American Society of Anesthesiologists class > 3
- need for combined resection of other organs
- laparoscopic/robotic access
- severe heart disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TST-TriStaple(3lines stapler)TechnologyDuodenal stump closed using a Tristaple ( three-lines linear stapler) device | Device | TST-TriStaple(3lines stapler)Technology |
| other conventional techniquesAlso: double-line linear stapler with manual reinforcement, manual suture, purse string suture, double-line linear stapler without manual reinforcementDuodenal stump closed using other conventional techniques entailing manual suture or mechanical devices with only two lines of sutures. | Other | OCT (other conventional techniques) |
Primary outcome
incidence of duodenal stump leak
Time frame: within 30/60 days from operation
The aim of this study is to evaluate if duodenal stump closure using tri-staple technology can significantly decrease the incidence of duodenal stump leakage to 1% as compared to other conventional methods (5%). So the primary endpoint is : - incidence of DSF, diagnosed on the basis of the presence of duodenal juice in the surgical drainage or its leakage through the abdominal wall, and confirmed by CT scan and/or fistulography.
7 secondary outcomes
cost of surgery
Time frame: within 90 days from operation
operative time for duodenal stump closure
Time frame: intraopeartively
short-term postoperative complications
Time frame: within 30 days from operation
blood loss
Time frame: intraopeartively
lenght of hospitalization
Time frame: 120 days after operation
Operative mortality
Time frame: 30 and 60 days after operation
Frequency of DSF by surgical volume
Time frame: one year
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2017.
- Background: PubMed 17899867Inghelmann R, Grande E, Francisci S, Verdecchia A, Micheli A, Baili P, Capocaccia R, De Angelis R. Regional estimates of stomach cancer burden in Italy. Tumori. 2007 Jul-Aug;93(4):367-73. doi: 10.1177/030089160709300407.
- Background: PubMed 19999909Aurello P, Bellagamba R, Rossi Del Monte S, D'Angelo F, Nigri G, Cicchini C, Ravaioli M, Ramacciato G. Apoptosis and microvessel density in gastric cancer: correlation with tumor stage and prognosis. Am Surg. 2009 Dec;75(12):1183-8.
- Background: PubMed 25368226Aurello P, Magistri P, Nigri G, Petrucciani N, Novi L, Antolino L, D'Angelo F, Ramacciato G. Surgical management of microscopic positive resection margin after gastrectomy for gastric cancer: a systematic review of gastric R1 management. Anticancer Res. 2014 Nov;34(11):6283-8.
- Background: PubMed 12025834Martin RC 2nd, Jaques DP, Brennan MF, Karpeh M. Achieving RO resection for locally advanced gastric cancer: is it worth the risk of multiorgan resection? J Am Coll Surg. 2002 May;194(5):568-77. doi: 10.1016/s1072-7515(02)01116-x.
- Background: PubMed 19001484Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, Oxman AD, Moher D; CONSORT group; Pragmatic Trials in Healthcare (Practihc) group. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008 Nov 11;337:a2390. doi: 10.1136/bmj.a2390.
- Results publication: PubMed 24399492Orsenigo E, Bissolati M, Socci C, Chiari D, Muffatti F, Nifosi J, Staudacher C. Duodenal stump fistula after gastric surgery for malignancies: a retrospective analysis of risk factors in a single centre experience. Gastric Cancer. 2014 Oct;17(4):733-44. doi: 10.1007/s10120-013-0327-x. Epub 2014 Jan 8.
- Results publication: PubMed 20143272Cozzaglio L, Coladonato M, Biffi R, Coniglio A, Corso V, Dionigi P, Gianotti L, Mazzaferro V, Morgagni P, Rosa F, Rosati R, Roviello F, Doci R. Duodenal fistula after elective gastrectomy for malignant disease : an italian retrospective multicenter study. J Gastrointest Surg. 2010 May;14(5):805-11. doi: 10.1007/s11605-010-1166-2. Epub 2010 Feb 9.
- Results publication: PubMed 3729708Rossi JA, Sollenberger LL, Rege RV, Glenn J, Joehl RJ. External duodenal fistula. Causes, complications, and treatment. Arch Surg. 1986 Aug;121(8):908-12. doi: 10.1001/archsurg.1986.01400080050009.
- Results publication: PubMed 13725742EDMUNDS LH Jr, WILLIAMS GM, WELCH CE. External fistulas arising from the gastro-intestinal tract. Ann Surg. 1960 Sep;152(3):445-71. doi: 10.1097/00000658-196009000-00009. No abstract available.
- Results publication: PubMed 6624121Tarazi R, Coutsoftides T, Steiger E, Fazio VW. Gastric and duodenal cutaneous fistulas. World J Surg. 1983 Jul;7(4):463-73. doi: 10.1007/BF01655935. No abstract available.
- Results publication: PubMed 26352529Kim W, Kim HH, Han SU, Kim MC, Hyung WJ, Ryu SW, Cho GS, Kim CY, Yang HK, Park DJ, Song KY, Lee SI, Ryu SY, Lee JH, Lee HJ; Korean Laparo-endoscopic Gastrointestinal Surgery Study (KLASS) Group. Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01). Ann Surg. 2016 Jan;263(1):28-35. doi: 10.1097/SLA.0000000000001346.
- Results publication: PubMed 17404848Pedrazzani C, Marrelli D, Rampone B, De Stefano A, Corso G, Fotia G, Pinto E, Roviello F. Postoperative complications and functional results after subtotal gastrectomy with Billroth II reconstruction for primary gastric cancer. Dig Dis Sci. 2007 Aug;52(8):1757-63. doi: 10.1007/s10620-006-9655-6. Epub 2007 Apr 3.
- Individual participant dataSharing planned: No
Related trials for Gastric Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
Not yet recruitingPhase 1
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
Gastric Cancer (GC)
RecruitingPhase 3
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
Gastric, Esophagogastric Junction
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Maurizio Degiuli, MD Prof principal investigator
University of Turin, San Luigi University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing TST-TriStaple(3lines stapler)Technology and other conventional techniques in people with Gastric Cancer and Duodenal Stump Leak, run by University of Turin, Italy at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Sep 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Rossella Reddavid, MD (+393479848651, rossella.reddavid@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
incidence of duodenal stump leak (time frame: within 30/60 days from operation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03277144, which also lists 20 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2017.